Justice Samuel Alito on Monday afternoon granted a one-week administrative stay of the Fifth Circuit’s May 1 order in the Louisiana mifepristone case, leaving in place the Food and Drug Administration’s 2023 rules that allow the drug to be prescribed by telehealth and dispensed by mail. The stay runs through 5 p.m. on Monday, May 11. It says nothing about who is likely to prevail. It buys the Court a week to read the briefs.
The order came in two consolidated emergency applications: Danco Laboratories v. Louisiana (No. 25A1207), filed by the manufacturer of the brand-name drug Mifeprex, and GenBioPro v. Louisiana (No. 25A1208), filed by the generic manufacturer. Both companies are defendant-intervenors in a case the State of Louisiana brought against the FDA in October 2025, arguing that the agency’s 2023 elimination of the in-person dispensing requirement violated the Administrative Procedure Act. The applications were filed Saturday morning. Alito, who handles emergency matters from the Fifth Circuit, granted the administrative stay roughly forty-eight hours later.
An administrative stay is not a ruling on the merits. It is the Court’s housekeeping tool, used when an applicant arrives faster than the justices can responsibly digest the papers. The order Alito signed Monday paused the Fifth Circuit’s May 1 ruling so that, in the interval before the full Court decides whether to grant or deny a longer stay, the regulatory ground does not shift twice. The mechanism is procedural. The underlying dispute is not.
What the Fifth Circuit did on May 1
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit granted Louisiana’s motion to stay the operation of the FDA’s 2023 REMS modifications pending appeal. REMS, the Risk Evaluation and Mitigation Strategy, is the safety program the agency attaches to a small set of drugs whose risk profiles warrant something more than ordinary prescription controls. Mifepristone has carried a REMS since the FDA first approved it in 2000. The 2023 modifications, which the panel ordered stayed, removed the requirement that the drug be dispensed in person by a certified provider, opened mail dispensation through certified pharmacies, and permitted telehealth prescribing. The Fifth Circuit’s order would have reinstated the in-person requirement nationwide, not just in Louisiana.
The underlying litigation has a longer arc. Louisiana filed suit in October 2025 in the Western District of Louisiana, arguing the FDA’s 2023 action was arbitrary and capricious. In April 2026, the district court paused proceedings for six months at the FDA’s request, to allow the agency to complete an internal review of the drug’s safety record. The state moved for an injunction pending appeal; the Fifth Circuit panel granted it. That order, dated May 1, is what reached Alito over the weekend.
What the manufacturers argued
Danco told the Court that the Fifth Circuit’s order was "unprecedented" and would "inject immediate confusion and upheaval into highly time-sensitive medical decisions." GenBioPro argued the order "has unleashed regulatory chaos" and asked the justices to "allow the years-long status quo to remain in force while the Food and Drug Administration completes its ongoing review." Both companies framed the harm as operational: pharmacies that had built distribution systems around mail dispensation would need to retool within days, and patients with telehealth appointments scheduled for the coming week would lose access regardless of where they lived.
Louisiana, in its opposition, framed its injuries in sovereignty terms. Attorney General Liz Murrill argued the state suffered harm from its inability to enforce its own abortion statutes when out-of-state shipments reach Louisiana patients, and from Medicaid emergency-room costs the state attributes to complications. After Alito’s order Monday, Murrill issued a written statement calling the administrative stay "temporary" and saying she remained "confident life and law will win in the end."
The administrative stay is temporary, and I am confident life and law will win in the end. — Louisiana Attorney General Liz Murrill, written statement, May 4, 2026
Who decides, who pays, and what changes on May 11
The Court has three procedural choices when the administrative stay expires. It can grant a longer stay, leaving the 2023 rules in force while the Fifth Circuit hears the merits of Louisiana’s appeal. It can deny the stay, in which case the Fifth Circuit’s May 1 order takes effect and in-person dispensing is reinstated nationwide. Or it can extend the administrative stay again to take more time. None of those choices is a ruling on whether the FDA acted lawfully in 2023. That question, if the Court reaches it, is months away at the earliest.
The operational consequences run along the in-person line. The 2023 REMS modifications enabled a category of practice that did not exist for the drug’s first twenty-three years on the U.S. market: a clinician in one state could see a patient in another over video, write a prescription, and have a certified pharmacy mail the medication to the patient’s home. Roughly a fifth of mifepristone dispensations in 2024 ran through that pathway, according to figures the FDA cited in its 2023 record. If the Fifth Circuit’s order survives the Court’s review, those prescriptions revert to in-person provision at certified clinics. Clinic capacity, not pharmacy capacity, becomes the binding constraint. The states with the smallest provider footprints absorb the largest share of the shift.
The political incentives on both sides are visible in who chose to file what, when. Danco and GenBioPro filed within forty-eight hours of the Fifth Circuit’s order because their commercial exposure is direct: a mail-only distribution pipeline does not transition to in-person dispensation in a week. Louisiana filed in October 2025, when the FDA was sitting on a paused internal review, because the state preferred a judicial path to a regulatory one. The 2023 REMS modifications, like most agency actions, are easier to challenge in court than to unwind through notice-and-comment rulemaking, which can run years and is reviewable on the same APA grounds the state is asserting now. The judicial route is faster and, by the time it reaches the Supreme Court, narrows to a question the agency’s own scientific record cannot directly answer.
For patients, the calendar this week is the operative one. Telehealth appointments scheduled before May 11 will proceed under the existing rules. Appointments scheduled after that date are contingent on the order the Court has not yet issued. Kelly Baden, vice president for public policy at the Guttmacher Institute, said in a statement Monday that "nothing short of full access to all methods of abortion care for everyone who needs it is acceptable" and that the institute was monitoring access state by state. The clinical baseline, in other words, is unstable on a one-week horizon. Whatever the Court decides next Monday will be the operational ground for at least the next several months of the Fifth Circuit appeal.
The procedural map from here is short. The Court receives the FDA’s and the manufacturers’ reply briefs by Wednesday. The justices vote by Monday morning. The order, when it issues, is likely to be unsigned and unreasoned, in the form the Court has favored on its emergency docket for the past three terms. Justices Clarence Thomas and Alito are the most likely dissenters from any further stay; both have written separately in earlier orders on this drug. Whether the Court explains itself this time, after years of criticism of its shadow-docket practice, is the second question Monday will answer.